Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

'Flu' and structure-based drug design

¹Structural Biology Programme, European Molecular Biology Laboratory, Heidelberg, Germany. wade@embl-heidelberg.de

Structure (London, England : 1993)

|October 23, 1997

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

On the determinants of electron transfer reorganization energy in a cytochrome P450: cytochrome b5 complex. A combined quantum mechanics and molecular dynamics simulation study.

The Journal of chemical physics·2025

Same author

Graphene BioFET sensors for SARS-CoV-2 detection: a multiscale simulation approach.

Nanoscale advances·2022

Same author

Pulmonary Arterial Pruning and Longitudinal Change in Percent Emphysema and Lung Function: The Genetic Epidemiology of COPD Study.

Chest·2021

Same author

Protein conformational flexibility modulates kinetics and thermodynamics of drug binding.

Nature communications·2017

Same author

Three steps to gold: mechanism of protein adsorption revealed by Brownian and molecular dynamics simulations.

Physical chemistry chemical physics : PCCP·2016

Same author

Molecular simulations reveal that the long range fluctuations of human DPP III change upon ligand binding.

Molecular bioSystems·2015

Same journal

Cryo-EM structure of the Arabidopsisthaliana ribosome in translating and non-translating states.

Structure (London, England : 1993)·2026

Same journal

Multifaceted effects of N-glycosylation on amyloidogenic κ light chains in AL amyloidosis.

Structure (London, England : 1993)·2026

Same journal

Near-complete cryo-EM structure of the Klebsiella pneumoniae podophage RAN69 reveals tail fiber-spike interface and a divergent pre-ejectosome.

Structure (London, England : 1993)·2026

Same journal

Saxiphilin is a broad-spectrum toxin sponge for C13-modified saxitoxins.

Structure (London, England : 1993)·2026

Same journal

Cryo-EM structure of YfdQ reveals a widespread family of bacteriophage-associated proteins with shell-like assemblies.

Structure (London, England : 1993)·2026

Same journal

An extracellular allosteric gate modulates the ligand efficacy of GPR119.

Structure (London, England : 1993)·2026

See all related articles

New influenza drugs targeting viral neuraminidase (NA) and haemagglutinin (HA) show promise. Structure-based drug design offers a potent strategy against influenza, overcoming limitations of current vaccines and antivirals.

Area of Science:

Virology
Drug Discovery
Structural Biology

Background:

Influenza poses a constant pandemic threat, with existing vaccines offering limited efficacy.
Current antiviral drugs like amantadine and rimantadine are hampered by side effects and rapid viral resistance.
The neuraminidase (NA) and haemagglutinin (HA) surface glycoproteins of influenza are key targets for therapeutic intervention.

Purpose of the Study:

To review the application of structure-based drug design (SBDD) for developing novel anti-influenza agents.
To highlight SBDD strategies targeting influenza neuraminidase (NA) and haemagglutinin (HA).
To discuss the potential for new, specific, and potent influenza drugs.

Main Methods:

Utilizing the crystal structure of influenza neuraminidase (NA), first determined in 1983.

Related Experiment Videos

Applying structure-based drug design principles to create novel inhibitors.

Focusing on drug candidates that target viral surface glycoproteins NA and HA.

Main Results:

Advances in understanding NA and HA structures enable rational drug design.
Structure-based approaches have led to the development of potent NA inhibitors.
This methodology holds promise for creating effective anti-influenza therapies.

Conclusions:

Structure-based drug design is a powerful approach for developing novel influenza therapeutics.
Targeting NA and HA offers a viable strategy to combat influenza virus infections.
Future clinical applications of these rationally designed drugs are anticipated.